Active substance
Results for the substance nivolumab+relatlimab
1 result
About this active substance
The combination of Nivolumab + Relatlimab is an immunotherapy used to treat certain types of cancer, particularly advanced melanoma. It combines two drugs that work synergistically to enhance the immune response against cancer cells.
Nivolumab blocks the PD-1 protein, while Relatlimab inhibits the LAG-3 protein, both contributing to T-cell activation. This combination may improve treatment efficacy compared to using a single drug.
Side effects may include fatigue, diarrhea, skin rash, and inflammation of internal organs. Close monitoring is essential to manage potential complications.
This therapy is administered under the supervision of an oncology specialist. Discuss the benefits and risks of this combination therapy with your doctor.
Nivolumab blocks the PD-1 protein, while Relatlimab inhibits the LAG-3 protein, both contributing to T-cell activation. This combination may improve treatment efficacy compared to using a single drug.
Side effects may include fatigue, diarrhea, skin rash, and inflammation of internal organs. Close monitoring is essential to manage potential complications.
This therapy is administered under the supervision of an oncology specialist. Discuss the benefits and risks of this combination therapy with your doctor.